Merck
CN
  • Intranasal substituted cathinone "bath salts" psychosis potentially exacerbated by diphenhydramine.

Intranasal substituted cathinone "bath salts" psychosis potentially exacerbated by diphenhydramine.

Journal of addiction medicine (2013-06-05)
Erik W Gunderson, Matthew G Kirkpatrick, Laura M Willing, Christopher P Holstege
ABSTRACT

In this report, we describe a case of intranasal "bath salts"-associated psychosis. Symptoms developed during a 3-week binge and were potentially exacerbated by oral diphenhydramine taken for insomnia. The clinical case conference includes expert discussion from 3 disciplines: emergency medicine toxicology, behavioral pharmacology, and addiction medicine. It is hoped that the discussion will provide insight into the clinical aspects and challenges of addressing acute substituted cathinone toxicity, including acute psychosis, a major adverse effect of bath salts consumption.

MATERIALS
Product Number
Brand
Product Description

Supelco
Diphenhydramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Diphenhydramine hydrochloride, ≥98% (HPLC)
Supelco
Diphenhydramine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Diphenhydramine hydrochloride, European Pharmacopoeia (EP) Reference Standard